Travere therapeutics presents data reinforcing clinical benefit of filspari® (sparsentan) in igan and late-breaking presentation in fsgs at asn kidney week 2024

Nearly 60% of patients with igan in the spartan study achieved complete remission when using filspari as first-line treatment spartacus study, protect open-label extension, and real-world evidence presentations highlight initial safety and efficacy data of filspari in combination treatment in igan late-breaking presentation demonstrates sparsentan delivered rapid and sustained proteinuria reduction, and long-term kidney health benefits in a subset of patients with genetic, often treatment resistant, fsgs san diego, oct. 26, 2024 (globe newswire) -- travere therapeutics, inc., (nasdaq: tvtx), presented new data further demonstrating the clinical benefit of filspari (sparsentan) in iga nephropathy (igan) and reinforcing its potential in focal segmental glomerulosclerosis (fsgs) at the american society of nephrology (asn) kidney week 2024. “the data presented at asn provided additional evidence that filspari is effective across all subgroups of igan patients studied to-date, and that it achieved significant levels of complete remission when used in newly diagnosed patients.
TVTX Ratings Summary
TVTX Quant Ranking